Hypothetical Patient Profiles

Based on characteristics of patients included in PALOMA-2
Click on the patient you would like to learn more about.

ibrance-aromatase-inhibitor-page-accordion-1

Why consider first-line IBRANCE + aromatase inhibitor?
MEDICAL HISTORY
Initially diagnosed with breast cancer >8 years ago
  • Treatment for EBC: lumpectomy, radiation, 5 years of anastrozole
  • 3-year disease-free interval
Complaint: Mild hip pain
  • ECOG performance status 0
  • Workup: bone scan reveals metastases
Diagnosis: Postmenopausal ER+/HER2- metastatic breast cancer
How Evelyn aligns with patients in PALOMA-21
*Not an actual patient.
EBC=early breast cancer; ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor.

ibrance-aromatase-inhibitor-page-accordion-2

Why consider first-line IBRANCE + aromatase inhibitor?
MEDICAL HISTORY
Initially diagnosed with breast cancer 6 years ago
  • Treatment for EBC: right modified radical mastectomy, chemotherapy, 5 years of anastrozole
  • 15-month disease-free interval
Complaint: Mild dry cough on exercise without fever
  • ECOG performance status 1
  • Workup: MRI detected metastases in the liver and lung
Diagnosis: Postmenopausal ER+/HER2- MBC
How Brenda aligns with patients in PALOMA-21
*Not an actual patient.
EBC=early breast cancer; ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor.
*Not an actual patient.
REFERENCE
1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936.